메뉴 건너뛰기




Volumn 10, Issue 4, 2008, Pages 277-281

Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results

Author keywords

Ankylosing spondylitis; Anti tumor necrosis factor therapy; Overlap disease; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; ISONIAZID; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; RIFAMPICIN; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

EID: 43249129925     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (17)

References (19)
  • 1
    • 0034048349 scopus 로고    scopus 로고
    • Anti-cytokine therapy for rheumatoid arthritis
    • Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
    • (2000) Annu Rev Med , vol.51 , pp. 207-229
    • Maini, R.N.1    Taylor, P.C.2
  • 2
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
    • Maini RN, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932-9.
    • (1999) Lancet , vol.354 , pp. 1932-1939
    • Maini, R.N.1    St Clair, E.W.2    Breedveld, F.3
  • 3
    • 43249101134 scopus 로고    scopus 로고
    • Charles P, Eliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF alpha therapy in rheumatoid arthritis. J Immunol 1999163:1521-8.
    • Charles P, Eliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF alpha therapy in rheumatoid arthritis. J Immunol 1999163:1521-8.
  • 4
    • 0142218539 scopus 로고    scopus 로고
    • Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis
    • II:ii-3
    • Flendrie M, Creemers MCW, Welsing PMJ, et al. Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl II):ii-3.
    • (2003) Ann Rheum Dis , vol.62 , Issue.SUPPL.
    • Flendrie, M.1    Creemers, M.C.W.2    Welsing, P.M.J.3
  • 5
    • 0036720662 scopus 로고    scopus 로고
    • Etanercept, infliximab and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow-up programme, in southern Sweden
    • for the South Swedish Arthritis group
    • Geborek P, Crnkic M, Petersson IF, for the South Swedish Arthritis group. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme, in southern Sweden. Ann Rheum Dis 2002:61:793-8.
    • (2002) Ann Rheum Dis , vol.61 , pp. 793-798
    • Geborek, P.1    Crnkic, M.2    Petersson, I.F.3
  • 6
    • 19944433874 scopus 로고    scopus 로고
    • Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
    • Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52.
    • (2005) Ann Rheum Dis , vol.64 , pp. 246-252
    • Feltelius, N.1    Fored, C.M.2    Blomqvist, P.3
  • 7
    • 20444481876 scopus 로고    scopus 로고
    • Treatment continuation in patients receiving biological agents or conventional DMARD therapy
    • Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1274-1279
    • Zink, A.1    Listing, J.2    Kary, S.3
  • 8
    • 3442891154 scopus 로고    scopus 로고
    • Infliximab dose and clinical status: Results of 2 studies in 1642 patients with rheumatoid arthritis
    • Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45.
    • (2004) J Rheumatol , vol.31 , pp. 1538-1545
    • Stern, R.1    Wolfe, F.2
  • 9
    • 33846090262 scopus 로고    scopus 로고
    • Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 20006;33:2433-9.
    • Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 20006;33:2433-9.
  • 10
    • 7044227564 scopus 로고    scopus 로고
    • Updated consensus statement on biological agents, specifically tumor necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist for the treatment of rheumatic diseases, 2004
    • II:ii2-12
    • Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004;63(Suppl II):ii2-12.
    • (2004) Ann Rheum Dis , vol.63 , Issue.SUPPL.
    • Furst, D.E.1    Breedveld, F.C.2    Kalden, J.R.3
  • 11
    • 20144367312 scopus 로고    scopus 로고
    • Safety of biologic therapies - an update
    • Keystone EC. Safety of biologic therapies - an update. J Rheumatol 2005;32(Suppl 74):8-12.
    • (2005) J Rheumatol , vol.32 , Issue.SUPPL. 74 , pp. 8-12
    • Keystone, E.C.1
  • 12
    • 33846657544 scopus 로고    scopus 로고
    • Infections during tumor necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients
    • Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumor necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007;46:327-34.
    • (2007) Rheumatology , vol.46 , pp. 327-334
    • Salliot, C.1    Gossec, L.2    Ruyssen-Witrand, A.3
  • 13
    • 0344876553 scopus 로고    scopus 로고
    • Infection and anti-tumor necrosis factor-alpha therapy
    • Zandman-Goddard G. Infection and anti-tumor necrosis factor-alpha therapy. IMAJ 2003;5:814-16.
    • (2003) IMAJ , vol.5 , pp. 814-816
    • Zandman-Goddard, G.1
  • 14
    • 0344583756 scopus 로고    scopus 로고
    • Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor alpha
    • Tweezer-Zaks N, Shiloach E, Spivak A, Rapoport M, Novis B, Langevitz P. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor alpha. IMAJ 2003;5:829-30.
    • (2003) IMAJ , vol.5 , pp. 829-830
    • Tweezer-Zaks, N.1    Shiloach, E.2    Spivak, A.3    Rapoport, M.4    Novis, B.5    Langevitz, P.6
  • 15
    • 2642539404 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer
    • Symmons DPM, Silman AJ. Anti-tumor necrosis factor therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer. Arthritis Rheum 50:1703-6.
    • Arthritis Rheum , vol.50 , pp. 1703-1706
    • Symmons, D.P.M.1    Silman, A.J.2
  • 16
    • 27844511909 scopus 로고    scopus 로고
    • The risk of lymphoma development in autoimmune diseases: A meta-analysis
    • Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
    • (2005) Arch Intern Med , vol.165 , pp. 2337-2344
    • Zintzaras, E.1    Voulgarelis, M.2    Moutsopoulos, H.M.3
  • 17
    • 34948854326 scopus 로고    scopus 로고
    • B-cell lymphoproliferation in chronic inflammatory rheumatic diseases
    • Hansen A, Lipsky PE. Dorner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 2007;3:561-9.
    • (2007) Nat Clin Pract Rheumatol , vol.3 , pp. 561-569
    • Hansen, A.1    Lipsky, P.E.2    Dorner, T.3
  • 18
    • 34248547187 scopus 로고    scopus 로고
    • The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19562 patients during 89710 person-years of observation
    • Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19562 patients during 89710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
    • (2007) Arthritis Rheum , vol.56 , pp. 1433-1439
    • Wolfe, F.1    Michaud, K.2
  • 19
    • 34147219117 scopus 로고    scopus 로고
    • Survival of TNF antagonists in spondyloarthritis is better thdn in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
    • Carmona L, Gomez-Reino IJ. Survival of TNF antagonists in spondyloarthritis is better thdn in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
    • (2006) Arthritis Res Ther , vol.8
    • Carmona, L.1    Gomez-Reino, I.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.